WuXi AppTec Co Ltd banner

WuXi AppTec Co Ltd
SSE:603259

Watchlist Manager
WuXi AppTec Co Ltd Logo
WuXi AppTec Co Ltd
SSE:603259
Watchlist
Price: 100.19 CNY 0.95% Market Closed
Market Cap: ¥298.9B

EV/OCF

15.4
Current
6%
More Expensive
vs 3-y average of 14.5

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
15.4
=
Enterprise Value
¥264.3B
/
Operating Cash Flow
¥17.2B

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
15.4
=
Enterprise Value
¥264.3B
/
Operating Cash Flow
¥17.2B

Valuation Scenarios

WuXi AppTec Co Ltd is trading above its 3-year average

If EV/OCF returns to its 3-Year Average (14.5), the stock would be worth ¥94.56 (6% downside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-6%
Maximum Upside
+35%
Average Upside
19%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 15.4 ¥100.19
0%
3-Year Average 14.5 ¥94.56
-6%
5-Year Average 17.6 ¥114.55
+14%
Industry Average 20.1 ¥130.54
+30%
Country Average 20.8 ¥135.43
+35%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
CN
WuXi AppTec Co Ltd
SSE:603259
298.9B CNY 15.4 15.6
US
PerkinElmer Inc
LSE:0KHE
1T USD 1 774.1 4 280.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
175.6B USD 25.5 26.2
US
Danaher Corp
NYSE:DHR
126.4B USD 21.5 34.3
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 36.2 46.1
CH
Lonza Group AG
SIX:LONN
34.3B CHF 31.3 -119.7
US
Agilent Technologies Inc
NYSE:A
32.3B USD 24.3 25.1
US
Waters Corp
NYSE:WAT
30.5B USD 47.3 47.5
US
IQVIA Holdings Inc
NYSE:IQV
27.3B USD 14.7 20.1
US
Mettler-Toledo International Inc
NYSE:MTD
25.7B USD 29 29.6
FR
Sartorius Stedim Biotech SA
PAR:DIM
15.4B EUR 24.7 58.6

Market Distribution

In line with most companies in China
Percentile
39th
Based on 6 190 companies
39th percentile
15.4
Low
0 — 11.5
Typical Range
11.5 — 39.2
High
39.2 —
Distribution Statistics
China
Min 0
30th Percentile 11.5
Median 20.8
70th Percentile 39.2
Max 266 666.7

WuXi AppTec Co Ltd
Glance View

In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.

Intrinsic Value
102.33 CNY
Undervaluation 2%
Intrinsic Value
Price ¥100.19
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett